ORMP Stock — Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc. (ORMP)

Updated October 16, 2026.

ORMP is a Stock. its distribution rate is 6.14%, its trailing-12-month yield is 6.14%. Dividend Vision Distribution Safety Score™ is 50/100 (Unproven). Total return is 104259.0% over the past 22.6 years, 103322.0 points ahead of SPY at 937.0%.

Oramed Pharmaceuticals is a biopharmaceutical company focused on developing oral delivery technologies for therapeutic proteins, including an oral insulin capsule in phase III clinical trials for diabetes treatment and oral vaccine candidates for COVID-19 through a license agreement with Oravax Medical. The company does not maintain a regular distribution schedule; it has made special or one-time distributions that may not recur. This security appeals primarily to investors seeking exposure to early-stage pharmaceutical development rather than those focused on dependable recurring income.

ORMP performance versus SPY

Price and return data through 2026-10-16.

Total return is 104259.0% over the past 22.6 years, 103322.0 points ahead of SPY at 937.0%. Over the past year its total return — price change plus distributions reinvested — is 92.3%. Its deepest 1-year drawdown was 23.9%.

ORMP key facts

Distribution Safety Score™

50 · Unproven

Asset type

Stock

Asset class

Equity

Inception date

03/19/2004

Distribution rate

6.14%

Trailing yield

6.14%

Last close

$4.07 (as of 2026-10-16)

Market cap

$169,301,231

Average volume

277084.0

Dividend

$0.25

Ex-dividend date

01/16/2026

Payment date

01/26/2026

Beta

1.276

Payout ratio

11.3%

P/E ratio

0.99

EPS

$4.13

How Dividend Vision calculates yield and returns

Distribution rate (6.14%) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield (6.14%) is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

ORMP risks and drawbacks

The deepest 1-year drawdown on record here is 23.9%.

More on ORMP

• All tickers starting with O

Tagged: Healthcare, Dividend.

Frequently asked questions